This is consistent with our findings that CXCL5, a CXCR2 ligand, is expressed by tumor cells in a DDR1-dependent manner and drives neutrophil activation and NET formation (Figure 2; Figure 6, A–D; and Supplemental Figure 1). Here, CXCR2 is linked to neoplasm.